These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 22612696)

  • 41. Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends.
    Sohail MF; Rehman M; Sarwar HS; Naveed S; Salman O; Bukhari NI; Hussain I; Webster TJ; Shahnaz G
    Int J Nanomedicine; 2018; 13():3145-3161. PubMed ID: 29922053
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The performance of nanocarriers for transmucosal drug delivery.
    Csaba N; Garcia-Fuentes M; Alonso MJ
    Expert Opin Drug Deliv; 2006 Jul; 3(4):463-78. PubMed ID: 16822222
    [TBL] [Abstract][Full Text] [Related]  

  • 43. pH-Responsive carriers for oral drug delivery: challenges and opportunities of current platforms.
    Liu L; Yao W; Rao Y; Lu X; Gao J
    Drug Deliv; 2017 Nov; 24(1):569-581. PubMed ID: 28195032
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?
    Juillerat-Jeanneret L
    Drug Discov Today; 2008 Dec; 13(23-24):1099-106. PubMed ID: 18848640
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nanocrystal technology in the delivery of poorly soluble drugs: an overview.
    Nagarwal RC; Kumar R; Dhanawat M; Das N; Pandit JK
    Curr Drug Deliv; 2011 Jul; 8(4):398-406. PubMed ID: 21453258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs.
    Banerjee S; Pillai J
    Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):499-515. PubMed ID: 31104522
    [No Abstract]   [Full Text] [Related]  

  • 48. Recent Developments in the Area of Click-Crosslinked Nanocarriers for Drug Delivery.
    Dai Y; Chen X; Zhang X
    Macromol Rapid Commun; 2019 Feb; 40(3):e1800541. PubMed ID: 30417477
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs.
    Managuli RS; Raut SY; Reddy MS; Mutalik S
    Expert Opin Drug Deliv; 2018 Aug; 15(8):787-804. PubMed ID: 30025212
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies.
    Galindo-Rodriguez SA; Allemann E; Fessi H; Doelker E
    Crit Rev Ther Drug Carrier Syst; 2005; 22(5):419-64. PubMed ID: 16313233
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The ligand nanoparticle conjugation approach for targeted cancer therapy.
    Karra N; Benita S
    Curr Drug Metab; 2012 Jan; 13(1):22-41. PubMed ID: 21892918
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel lactoferrin-modified β-cyclodextrin nanocarrier for brain-targeting drug delivery.
    Ye Y; Sun Y; Zhao H; Lan M; Gao F; Song C; Lou K; Li H; Wang W
    Int J Pharm; 2013 Dec; 458(1):110-7. PubMed ID: 24126038
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PEGylated nanocarriers: A promising tool for targeted delivery to the brain.
    Gajbhiye KR; Pawar A; Mahadik KR; Gajbhiye V
    Colloids Surf B Biointerfaces; 2020 Mar; 187():110770. PubMed ID: 31926790
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Strategies for drug delivery to the central nervous system by systemic route.
    Kasinathan N; Jagani HV; Alex AT; Volety SM; Rao JV
    Drug Deliv; 2015 May; 22(3):243-57. PubMed ID: 24471801
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nanocarriers for brain specific delivery of anti-retro viral drugs: challenges and achievements.
    Varghese NM; Senthil V; Saxena SK
    J Drug Target; 2018 Mar; 26(3):195-207. PubMed ID: 28866957
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Advanced engineered nanoparticulate platforms to address key biological barriers for delivering chemotherapeutic agents to target sites.
    Cao J; Huang D; Peppas NA
    Adv Drug Deliv Rev; 2020 Dec; 167():170-188. PubMed ID: 32622022
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
    Agrawal M; Saraf S; Saraf S; Antimisiaris SG; Chougule MB; Shoyele SA; Alexander A
    J Control Release; 2018 Jul; 281():139-177. PubMed ID: 29772289
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of nanocarriers containing peptide and protein drugs.
    Griffin BT; Guo J; Presas E; Donovan MD; Alonso MJ; O'Driscoll CM
    Adv Drug Deliv Rev; 2016 Nov; 106(Pt B):367-380. PubMed ID: 27320644
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design of Zein Conjugation and Surface Modification for Targeting Drug Delivery.
    Tran PH; Tran TT
    Curr Drug Targets; 2020; 21(4):406-415. PubMed ID: 31518220
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeted nanoparticles with novel non-peptidic ligands for oral delivery.
    des Rieux A; Pourcelle V; Cani PD; Marchand-Brynaert J; Préat V
    Adv Drug Deliv Rev; 2013 Jun; 65(6):833-44. PubMed ID: 23454185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.